These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 16469084)

  • 21. Leuprolide acetate given by a subcutaneous extended-release injection: less of a pain?
    Cox MC; Scripture CD; Figg WD
    Expert Rev Anticancer Ther; 2005 Aug; 5(4):605-11. PubMed ID: 16111462
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Clinical effects of a 3-month formulation LH-RH agonist, TAP-144-SR (3M) in prostate cancer patients].
    Koiso K; Yamanaka H; Ito K; Yoshinaka R; Uchida S; Yokokawa K
    Hinyokika Kiyo; 2002 Dec; 48(12):771-9. PubMed ID: 12613015
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Follicular mucinosis and mycosis-fungoides-like drug eruption due to leuprolide acetate: a case report and review.
    Shalin SC; Brantley J; Diwan AH
    J Cutan Pathol; 2012 Nov; 39(11):1022-5. PubMed ID: 22882386
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Leuprorelin acetate granulomas: recurrent subcutaneous nodules mimicking metastatic deposits at injections sites.
    Saxby M
    BJU Int; 2003 Jan; 91(1):125. PubMed ID: 12614269
    [No Abstract]   [Full Text] [Related]  

  • 25. [Leuprorelin acetate depot].
    Mashimo T
    Nihon Rinsho; 2000 Jul; 58 Suppl():191-6. PubMed ID: 11022712
    [No Abstract]   [Full Text] [Related]  

  • 26. Life-threatening anaphylaxis to leuprorelin acetate depot: case report and review of the literature.
    Fujisaki A; Kondo Y; Goto K; Morita T
    Int J Urol; 2012 Jan; 19(1):81-4. PubMed ID: 22050405
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Clinical effects of a 3-month formulation LH-RH agonist, TAP-144-SR (3M) in prostate cancer patients].
    Koiso K; Akaza H; Naito S; Usami M; Tsukamoto T; Shimazaki J; Kotake T; Yamanaka H; Oohashi Y; Yoshinaka R; Onouchi H; Yokokawa K
    Hinyokika Kiyo; 2002 Dec; 48(12):781-95. PubMed ID: 12613016
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Time to normalization of testosterone after withdrawal of long time LH-RH agonist therapy in prostate cancer].
    Kaku H; Tsushima T; Nasu Y; Kumon H
    Nihon Rinsho; 2002 Dec; 60 Suppl 11():182-7. PubMed ID: 12599568
    [No Abstract]   [Full Text] [Related]  

  • 29. Hot flashes during androgen deprivation therapy with luteinizing hormone-releasing hormone agonist combined with steroidal or nonsteroidal antiandrogen for prostate cancer.
    Sakai H; Igawa T; Tsurusaki T; Yura M; Kusaba Y; Hayashi M; Iwasaki S; Hakariya H; Hara T; Kanetake H
    Urology; 2009 Mar; 73(3):635-40. PubMed ID: 19038426
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Nonalcoholic fatty liver disease induced by leuprorelin acetate.
    Gabbi C; Carubbi F; Losi L; Loria P; Costantini M; Bertolotti M; Carulli N
    J Clin Gastroenterol; 2008 Jan; 42(1):107-10. PubMed ID: 18097299
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Anaphylaxis to leuprolide acetate depot injection during treatment for prostate cancer.
    Grant JP; Levinson AW
    Clin Genitourin Cancer; 2007 Mar; 5(4):284-6. PubMed ID: 17553209
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Does needle size matter? Patient experience of luteinising hormone-releasing hormone analogue injection.
    Montgomery BS; Borwell JP; Higgins DM
    Prostate Cancer Prostatic Dis; 2005; 8(1):66-8. PubMed ID: 15700050
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Early development of castrate resistance varies with different dosing regimens of luteinizing hormone releasing hormone agonist in primary hormonal therapy for prostate cancer.
    Blumberg JM; Kwon EO; Cheetham TC; Niu F; Shapiro CE; Pacificar J; Loo RK; Williams SG; Chien GW
    Urology; 2011 Feb; 77(2):412-6. PubMed ID: 21111460
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Leuprorelin acetate in prostate cancer: a European update.
    Persad R
    Int J Clin Pract; 2002 Jun; 56(5):389-96. PubMed ID: 12137449
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of tolerability and adverse events following treatment with two GnRH agonists in patients with advanced prostate cancer.
    Shore ND; Sieber P; Schimke L; Perzin A; Olsen S
    Urol Nurs; 2013; 33(5):236-44, 248. PubMed ID: 24354113
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Leuprolide acetate-induced generalized papular eruption.
    Burris K; Ding CY; Lim GF
    J Drugs Dermatol; 2014 Jun; 13(6):755-7. PubMed ID: 24918569
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Failure of gonadotropin-releasing hormone agonists with and without sterile abscess formation at depot sites: insight into mechanisms?
    Daskivich TJ; Oh WK
    Urology; 2006 May; 67(5):1084.e15-7. PubMed ID: 16698377
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Luteinizing hormone-releasing hormone for prostate cancer in a hemodialysis patient: a case report].
    Mizusawa H; Kontani K; Okaneya T; Yoneyama T
    Hinyokika Kiyo; 1997 Jun; 43(6):421-3. PubMed ID: 9250492
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Leuprorelin, triptorelin: new indications. Locally advanced prostate cancer: minimally assessed me-toos.
    Prescrire Int; 2007 Dec; 16(92):243. PubMed ID: 18092407
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Leuprolide acetate-induced dermatitis herpetiformis.
    Grimwood RE; Guevara A
    Cutis; 2005 Jan; 75(1):49-52. PubMed ID: 15732435
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.